These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 8557344)
21. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Venkatesan MM; Hartman AB; Newland JW; Ivanova VS; Hale TL; McDonough M; Butterton J Infect Immun; 2002 Jun; 70(6):2950-8. PubMed ID: 12010984 [TBL] [Abstract][Full Text] [Related]
22. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. Simon JK; Maciel M; Weld ED; Wahid R; Pasetti MF; Picking WL; Kotloff KL; Levine MM; Sztein MB Clin Immunol; 2011 May; 139(2):185-92. PubMed ID: 21388888 [TBL] [Abstract][Full Text] [Related]
23. [Construction and characterization of a live attenuated Shigella flexneri 2a vaccine strain, sf301 Delta virG and dsbA33G]. Yang XF; Zhou L; Zheng J; Si LS; Wang YL Wei Sheng Wu Xue Bao; 2005 Oct; 45(5):748-52. PubMed ID: 16342769 [TBL] [Abstract][Full Text] [Related]
24. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines. Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247 [TBL] [Abstract][Full Text] [Related]
25. Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines. Vindurampulle CJ; Attridge SR Infect Immun; 2003 Jan; 71(1):287-97. PubMed ID: 12496178 [TBL] [Abstract][Full Text] [Related]
27. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Oaks EV; Turbyfill KR Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Kotloff KL; Losonsky GA; Nataro JP; Wasserman SS; Hale TL; Taylor DN; Newland JW; Sadoff JC; Formal SB; Levine MM Vaccine; 1995 Apr; 13(5):495-502. PubMed ID: 7639017 [TBL] [Abstract][Full Text] [Related]
29. Genetic characterization and immunogenicity of coli surface antigen 4 from enterotoxigenic Escherichia coli when it is expressed in a Shigella live-vector strain. Altboum Z; Levine MM; Galen JE; Barry EM Infect Immun; 2003 Mar; 71(3):1352-60. PubMed ID: 12595452 [TBL] [Abstract][Full Text] [Related]
30. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates. Simon JK; Wahid R; Maciel M; Picking WL; Kotloff KL; Levine MM; Sztein MB Vaccine; 2009 Jan; 27(4):565-72. PubMed ID: 19022324 [TBL] [Abstract][Full Text] [Related]
31. Vaccine potential for inactivated shigellae. Osorio M; Bray MD; Walker RI Vaccine; 2007 Feb; 25(9):1581-92. PubMed ID: 17178431 [TBL] [Abstract][Full Text] [Related]
32. Immunization against the colonization factor antigen I of enterotoxigenic Escherichia coli by administration of a bivalent Salmonella typhimurium aroA strain. Guillobel HC; Luna MG; Camacho EF; Almeida DF; Ferreira LC Braz J Med Biol Res; 1998 Apr; 31(4):545-54. PubMed ID: 9698808 [TBL] [Abstract][Full Text] [Related]
33. Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes. Verma NK; Lindberg AA Vaccine; 1991 Jan; 9(1):6-9. PubMed ID: 2008803 [TBL] [Abstract][Full Text] [Related]
34. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a. Dharmasena MN; Osorio M; Takeda K; Stibitz S; Kopecko DJ Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046309 [TBL] [Abstract][Full Text] [Related]
35. DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. Anderson RJ; Pasetti MF; Sztein MB; Levine MM; Noriega FR Vaccine; 2000 Apr; 18(21):2193-202. PubMed ID: 10717338 [TBL] [Abstract][Full Text] [Related]
36. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Kotloff KL; Herrington DA; Hale TL; Newland JW; Van De Verg L; Cogan JP; Snoy PJ; Sadoff JC; Formal SB; Levine MM Infect Immun; 1992 Jun; 60(6):2218-24. PubMed ID: 1587589 [TBL] [Abstract][Full Text] [Related]
37. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. Van De Verg LL; Bendiuk NO; Kotloff K; Marsh MM; Ruckert JL; Puryear JL; Taylor DN; Hartman AB Vaccine; 1996 Aug; 14(11):1062-8. PubMed ID: 8879103 [TBL] [Abstract][Full Text] [Related]
38. Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen. Formal SB; Hale TL; Kapfer C; Cogan JP; Snoy PJ; Chung R; Wingfield ME; Elisberg BL; Baron LS Infect Immun; 1984 Nov; 46(2):465-9. PubMed ID: 6389344 [TBL] [Abstract][Full Text] [Related]